Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.. 2011.
The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.. 2011.
Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.. 2011.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.. 2011.
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.. 2010.
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.. 2010.
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.. 2010.
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.. 2010.
The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.. 2010.
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.. 2010.
The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.. 2010.
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther. 15:203-11.. 2010.
Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.. 2009.
Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.. 2009.
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.. 2009.
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.. 2009.
Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 83:2645-54.. 2009.